Clinical Research Directory

Inclusion Criteria: * Signature of the informed consent and consent to the use of personal data * Prostate Specific Antigen (PSA) \< 20 ng/mL * Unilateral organ-confined disease on MRI (performed according to ESUR recommendations and reported according to PiRads V.2) or PET-PSMA (performed according to the recommendations of the EANM and reported according to "EANM standardized reporting guidelines v1.0 for PSMA-PET") * Histological diagnosis of acinar-type prostate cancer unilateral on target biopsy and/or standard biopsy with ISUP \< 3 and ipsilateral on imaging investigations * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 * Life expectancy ≥ 5 years * Availability of the patient's pre-operative clinical data * Patients must be available to carry out the follow-up visits defined by the protocol * Absence of retroperitoneal, lymph nodal, bone or visceral metastatic lesions * Patients eligible for robot-assisted radical prostatectomy Exclusion Criteria: * Special histotypes of prostate cancer * Patients with PSA \> 20 ng/ml at diagnosis * Impossibility to perform MRI (with pacemakers, claustrophobia…) or PET-PSMA * Previous prostate surgery (TURP, adenomectomy) * Concomitant treatment with other antineoplastic drugs including investigational endocrine therapies * Serious underlying disease or uncontrolled medical condition including active and uncontrolled infections * Patients with dementia or psychiatric illness that limit compliance with study requirements or that could prevent understanding and/or signing the informed consent.